D-dimer test before cemiplimab for advanced skin cancer
Part of Heart & circulation clinical trials.
This trial looks at whether a simple blood test (D-dimer) taken before starting the drug cemiplimab can help predict how well the treatment works for advanced skin cancer. It aims to find out if this test can guide better care for patients with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced skin cancer (squamous cell carcinoma) that has spread or cannot be removed.
- You are about to start treatment with cemiplimab as part of your normal care.
- You have a D-dimer blood test within 7 days before your first cemiplimab dose.
- You are at least 18 years old.
- You are able to perform daily activities with little or no help (ECOG score 0–2).
- You have not had any immunotherapy for skin cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This trial tests whether the immunotherapy drug cemiplimab can treat advanced squamous cell skin cancer in people who have had a kidney transplant. It aims to see if the drug can shrink tumors while keeping the transplanted kidney working well.
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Hear when a new Cutaneous Squamous Cell Carcinoma (CSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.